IRWD · CIK 0001446847
What Ironwood Pharmaceuticals, Inc. told the SEC could break it.
Ironwood's disclosures revolve around its dependence on a single product and partner, and the financial and pricing pressure on it. Linaclotide partnerships were substantially all of its revenue, dominated by its LINZESS U.S. collaboration with AbbVie, so that one product's demand, pricing and AbbVie's commercialization drive results — and it now faces IRA Medicare drug-price negotiation setting LINZESS's net Medicare price at $136 effective January 2027. Against that backdrop it carries near-term financial risk: $200 million of convertible senior notes maturing in June 2026 and a $550 million revolver, set against a roughly $1.7 billion accumulated deficit. It also relies on third-party CDMOs to manufacture its pipeline asset apraglutide.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- substantially all revenue from linaclotide partnerships; AbbVie LINZESS US collaboration dominanthigh
Ironwood's revenue is overwhelmingly single-product/single-partner — linaclotide partnerships were substantially all revenue, with the AbbVie LINZESS U.S. collaboration the dominant share — so LINZESS demand, pricing, reimbursement or AbbVie's commercialization directly drive results.
“Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeable future.”
SEC filing →As of 2026
Liquidity & debt
- $200M Convertible Notes due June 2026; $550M revolver; $1.7B accumulated deficithigh
Ironwood carries $200M of 1.50% Convertible Senior Notes maturing June 2026 and a $550M secured revolving facility against a ~$1.7B accumulated deficit, concentrating near-term refinancing/repayment risk amid pricing pressure on its core product.
“Senior Notes, bearing an interest of 1.50% and due in June 2026, or the Convertible Senior Notes, and our $550.0 million secured revolving credit facility, or the Revolving Credit Facility.”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-price negotiation sets LINZESS MFP at $136 (Jan 2027); drug-pricing EOmedium
Under IRA Medicare drug-price negotiation, LINZESS's maximum fair price becomes a $136 net Medicare price effective January 1, 2027, and a April 2025 Executive Order directs HHS/FDA to further reduce drug prices and ease importation — pressuring Ironwood's dominant product's economics.
“the new Medicare net price as of January 1, 2027, is set to $136. The revised MFP for LINZESS was in line with our expectations.”
Supplier concentration
- apraglutide manufactured by third-party CDMOsmedium
Ironwood relies on third-party contract development and manufacturing organizations (CDMOs) to produce its pipeline asset apraglutide for clinical and future commercial use, exposing the program to CDMO capacity, quality and supply risk.
“We design and develop the manufacturing process for apraglutide together with contract development and manufacturing organizations, or CDMOs. We utilize these CDMOs to manufacture apraglutide for human use.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeable future.”
Cited →“The Company has linaclotide collaboration agreements with AbbVie for North America and AstraZeneca for China (including Hong”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch